Navigation Links
Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids
Date:5/31/2008

re than 100 million American adults have elevated total cholesterol. Of the 30 million Americans currently on lipid-altering therapies, the majority are not reaching treatment goals. Treatment guidelines endorsed by the National Cholesterol Education Panel, the American College of Cardiology and the AHA have called for more aggressive management of lipids, including a lower LDL goal for many patients, as well as more aggressive management of HDL and triglycerides.

About the Study

The efficacy and safety of TriLipix in combination with rosuvastatin was evaluated in a randomized, double-blind, controlled, 12-week, Phase III study of 1,445 patients with mixed dyslipidemia. Patients included in the study had multiple lipid problems, with an LDL greater than or equal to 130 mg/dL, triglycerides greater than or equal to 150 mg/dL and HDL less than 40 mg/dL for men and less than 50 mg/dL for women.

Patients were randomized to receive TriLipix (135mg) combined with either 10mg or 20mg of rosuvastatin, TriLipix monotherapy (135mg) or rosuvastatin monotherapy (10mg, 20mg or 40mg). The 40mg rosuvastatin monotherapy arm was included in the study to assess safety and adverse events, but was not included in the statistical analysis.

The primary efficacy comparisons were mean percent change in HDL and triglycerides in the combination compared to rosuvastatin monotherapy, and mean percent change in LDL in the combination compared to TriLipix monotherapy. The study met all of its primary endpoints. Patients treated with the combination of TriLipix 135mg and rosuvastatin 10mg had an increase in HDL of 20.3 percent and decrease in triglycerides of 47.1 percent compared to an HDL increase of 8.5 percent and triglyceride decrease of 24.4 percent with rosuvastatin 10mg alone. LDL decreased 37.2 percent with the combination compared to 6.5 percent with TriLipix 135mg monotherapy.

Patients treated with the combination of TriLipix 135mg and rosuvastatin 20
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014 Lumin Medical LLC, a ... of PatientTrak, the leading provider of on-demand patient tracking ... Illinois to Franklin, Wis. ... which means light and our mission is to provide ... increase efficiencies and reduce costs," said James Hermann ...
(Date:7/14/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a premerger notification under the ... the U.S. Federal Trade Commission (FTC) relating to ... About Valeant Pharmaceuticals International, Inc. ... VRX) is a multinational specialty pharmaceutical company that ...
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3
... 2012 Pharmatek Laboratories, Inc., a premier contract ... industry, announced that it has expanded its existing ... Automated Liquid Filling and Banding System. The addition of ... increases overall efficiency at the Phase 2 production ...
...  Swedish Covenant Hospital today announced the success of its ... Guided Surgery by Brainlab, the ultimate command and control ... option to use image guidance for a prone, occipital ... visualization in these types of procedures, and makes me ...
Cached Medicine Technology:Pharmatek Increases Liquid Filled Capsule Capacity 2Pharmatek Increases Liquid Filled Capsule Capacity 3Curve Image Guided Surgery Provides Swedish Covenant Hospital With a State-of-the-Art Command and Control Center for Information-Guided Surgery 2Curve Image Guided Surgery Provides Swedish Covenant Hospital With a State-of-the-Art Command and Control Center for Information-Guided Surgery 3
(Date:7/14/2014)... According to a recent study ... discovered a connection between women with high levels of ... Although doctors have theorized about the role stress plays ... to provide scientific support. , “Stress, if very significant, ... Larry Barmat, an OB/GYN who specializes in reproductive endocrinology ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 Jordan Valley ... of a new comprehensive cancer center set to open ... will be the only hospital west of I-15 in ... cancer services , Additionally, Jordan Valley Medical Center has ... and cancer treatment planning systems for radiation therapy, radiosurgery ...
(Date:7/14/2014)... According to a new market research report ... and Others), Devices (Power IC, Power Module & Power ... 2014 - 2020", the Power Electronics market is expected ... market is valued at $36.86 Billion and expected to ... The report also includes an in-depth analysis of the ...
(Date:7/14/2014)... Technology Institute (BTI) has entered into an agreement ... Roche, to identify novel drug candidates for the ... together BTI,s capabilities in novel antibody discovery and ... therapeutics, opening up the possibility of improved treatment ... , The collaboration makes use of BTI,s ...
(Date:7/14/2014)... Botanica Day Spa announced last month that ... at the day spa in down town Clearwater, FL ... other refreshments will be served as clients are invited ... products and great deals on spa services, including ... Dermaplaning (also known as “facial shaving”) is a simple ...
Breaking Medicine News(10 mins):Health News:Abington Health Physician Addresses Link Between Stress and Infertility 2Health News:Abington Health Physician Addresses Link Between Stress and Infertility 3Health News:Jordan Valley Medical Center Set to Break Ground with New $10 Million Cancer Center 2Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 2Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 3Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 4Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 5Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3
... study on maternal malnutrition in the first trimester of ... the newborn. Dr. Tessa .J. Rosé boom of the ... occurrence of coronary heart diseases in children and correlated ... of pregnancy. They opined that maternal malnutrition during the ...
... The latest fad in the United States of America ... below 18 years, is taking the buzzword seriously.,Last year ... celebrities joining the jing bang. This pledge has been ... according to some analysts who have studied the abstinence ...
... landmark decision, has ruled that henceforth donors of sperms and ... desire so. However if the donor feels not to reveal ... ruling the identity of the donors of sperms and eggs ... with far reaching consequences. ,The communiqué released by the ...
... the United States of America, a lawyer- Peter Angelos, who ... in Maryland, has announced that he is dragging Vodafone to ... to cell phone users who are said to have developed ... This case has raised eyebrows not only because of the ...
... we have seen the newspapers carrying a news article about ... died following a high strung cricket match between India and ... Dr. Diederick E. Grobbee has revealed that there is an ... a major game. ,As compared to the number of ...
... a loved one die. More tragic is when the decision ... thin thread. Most patients of road traffic accidents, severe stokes, ... situation where they live technically only on life support systems. ... is to give consent to the medical staff attending on ...
Cached Medicine News:Health News:Brain death – How to cope with it 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: